NYMC Faculty Publications

Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities

Author Type(s)

Faculty

DOI

10.3390/biomedicines10020331

Journal Title

Biomedicines

Document Type

Article

Publication Date

1-31-2022

Department

Pharmacology

Keywords

diabetes mellitus, drug development, drug discovery, lead molecules, new targets, type 2 diabetes

Disciplines

Medicine and Health Sciences

Abstract

There are substantial shortcomings in the drugs currently available for treatment of type 2 diabetes mellitus. The global diabetic crisis has not abated despite the introduction of new types of drugs and targets. Persistent unaddressed patient needs remain a significant factor in the quest for new leads in routine studies. Drug discovery methods in this area have followed developments in the market, contributing to a recent rise in the number of molecules. Nevertheless, troubling developments and fresh challenges are still evident. Recently, metformin, the most widely used first-line drug for diabetes, was found to contain a carcinogenic contaminant known as N-nitroso dimethylamine (NDMA). Therefore, purity and toxicity are also a big challenge for drug discovery and development. Moreover, newer drug classes against SGLT-2 illustrate both progress and difficulties. The same was true previously in the case of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Furthermore, researchers must study the importance of mechanistic characteristics of novel compounds, as well as exposure-related hazardous aspects of current and newly identified protein targets, in order to identify new pharmacological molecules with improved selectivity and specificity.

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 38
  • Usage
    • Abstract Views: 2
  • Captures
    • Readers: 142
  • Social Media
    • Shares, Likes & Comments: 33
see details

Share

COinS